The objective of this study was to investigate the inhibitory effect of cucurbitacin I (CuI) and Ecballium elaterium L. (fruit juice and chloroform extract) on breast cancer cells (MCF-7 and MDA-MB-231). The CuI content of E. elaterium fruit juice and chloroform extract was quantified using high performance liquid chromatography. The cytotoxic effects of the fruit juice, chloroform extract and CuI were determined by MTT, wound healing and colony formation assays; all had an anti-proliferative activity on the breast cancer cells. Clarifying the mechanisms of cucurbitacins will enable the identification of new molecular targets for breast cancer therapy.
SezikE. (1997) Research on the Turkish medicinal plant Ecballium elaterium.Chemistry of Natural Compounds, 33, 541–542.
2.
ChenJ.C., ChiuM.H., NieR.L., CordellG.A., QiuS.X. (2005) Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports, 22, 386–399.
3.
Greige-GergesH., KhalilR.A., MansourE.A., MagdalouJ., ChahineR., OuainiN. (2007) Cucurbitacins from Ecballium elaterium juice increase the binding of bilirubin and ibuprofen to albumin in human plasma. Chemico-Biological Interactions, 169, 53–62.
4.
ArslanM.S., BasuguyE., IbilogluI., BozdemirE., ZeytunH., SahinA., KaplanI., AydogduB., OtcuS. (2016) Effects of Ecballium elateriumon proinflammatory cytokines in a rat model of sepsis. Journal of Investigative Surgery, 29, 399–404.
5.
ElNaggarMB, ChalupovaM., PrazanovaG., ParakT., SvajdlenkaE., ZemlickaM., SuchyP. (2015) Hepatoprotective and proapoptotic effect of Ecballium elaterium on CCl4-induced hepatotoxicity in rats. Asian Pacific Journal of Tropical Medicine, 8, 526–531.
6.
AdwanG., SalamehY., AdwanK. (2011) Effect of ethanolic extract of Ecballium elaterium against Staphylococcus aureus and Candida albicans.Asian Pacific Journal of Tropical Biomedicine, 1, 456–460.
JafargholizadehN., ZargarS.J., YassaN., TavakoliS. (2016) Purification of cucurbitacins D, E, and I from Ecballium elaterium (L.) A. rich fruits and study of their cytotoxic effects on the AGS cell line. Asian Pacific Journal of Cancer Prevention, 17, 4631–4635.
9.
EyolE., TanrıverdiZ., KarakuşF., YılmazK., ÜnüvarS. (2016) Synergistic anti-proliferative effects of CuI and Irinotecan on human colorectal cancer cell lines. Journal of Clinical and Experimental Pharmacology, 6, 1–6.
10.
SayedZ.I.E., BadrW.H. (2012) Cucurbitacin glucosides and biological activities of the ethyl acetate fraction from ethanolic extract of Egyptian Ecballium elaterium.Journal of Applied Sciences Research, 8, 1252–1258.
11.
BohlooliS., JafariN., JahedS. (2012) Cytotoxic effect of freeze-dried extract of Ecballium elaterium fruit on gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cell lines. Journal of Gastrointestinal Cancer, 43, 579–583.
12.
ImenT., OlfaK., BoulilaA, SalouaF., NazihaM., JoséL., BelgacemH. (2015) Ecballium elaterium (L.) A. Rich. seed oil: chemical composition and antiproliferative effect on human colonic adenocarcinoma and fibrosarcoma cancer cell lines. The Arabian Journal of Chemistry, https://doi.org/10.1016/j.arabjc.2015.02.023.
13.
LeeD.H., IwanskiG.B., ThoennissenN.H. (2012) Cucurbitacin: ancient compound shedding new light on cancer treatment. The Scientific World Journal, 10, 413–418.
14.
ClericuzioM., MellaM., Vita-FinziP., ZemM., VidariG. (2004) Cucurbitane triterpenoids from Leucopaxillus gentianeus.Journal of Natural Products, 67, 1823–1828.
15.
LiuT., ZhangM., ZhangH., SunC., DengY. (2008) Inhibitory effects of cucurbitacin B onlaryngeal squamous cell carcinoma. Journal of Natural Products, 265, 1225–1232.
16.
WakimotoN., YinD., O'KellyJ., HarituniansT., KarlanB., SaidJ., XingH., KoefflerH. (2008) Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo.Cancer Science, 99, 1793–1797.
17.
AlghashamA.A. (2013) Cucurbitacins a promising target for cancer therapy. International Journal of Health Sciences, 7, 68–79.
18.
IshdorjG., JohnstonJ.B., GibsonS.B. (2011) Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B leukemic cells. BMC Cancer, 11, 268–280.
19.
RenY., KunY., Su'anS., ZhıL., JınY., XueD.H., JıanhuaS., LınlınZ. (2014) JSI124 inhibits breast cancer cell growth by suppressing the function of B cells via the downregulation of signal transducer and activator of transcription 3. Oncology Letters, 8, 928–932.
20.
Cho-RongS., DongK.Y., No-JoonS., UiJ.Y., A-RyeongG., Dong-GyuJ., JaeY.C., KeejungY., Jee-YinA., ChuW.N., WooJ.P., SeungY.Y., KyeW.P. (2014) Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling. Food and Chemical Toxicology, 64, 217–224.
21.
JungS.H., Youn-KyungL., Hyun-JuL., Nu-RiC., Manh-CuongV., My-DungH., Mi-SeonL., NguyenP., Hyeoung-JoonK., Je-JungL. (2014) Dendritic cells loaded with myeloma cells pretreated with a combinationof JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.Experimental Hematology, 42, 274–281.
GuangY., Shao-FengY., HaoX., PingZ., Jin-TangS., GangL. (2014) Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. The Journal of Biological Chemistry, 289, 10607–10619.
24.
IshdorjG., JohnstonJ.B., GibsonS.B. (2010) İnhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human b-leukemia cells to apoptosis. Molecular Cancer Therapeutics, 9, 3302–3314.
25.
TsengL., Pin-IH., Yu-RungC., Yu-ChihC., Yueh-ChingC., Yi-WeiC., Yuh-LihC., Han-ShuiH., Yuan-TzuL., Kuan-HsuanC., Chin-WenC., Shih-HwaC., De-MingY., Chen-HsenL. (2012) Targeting STAT3 pathway by cucurbitacin I diminishes self-renewaling and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Journal of Pharmacology and Experimental Therapeutics, 341, 410–423.
26.
JayaprakasamB., NavindraP.S., MuraleedharanG.N. (2003) Anticancer and anti-inflammatory activities of cucurbitacins from Cucurbita andreana.Cancer Letters, 189, 11–16.
27.
KnechtD.A., LaFleurR.A., AlemW.K., ChristianE.A., BeshirB.A., FenteanyG. (2010) Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. Plos One, 5, 1–11.
28.
KimH.J., KimJ.K. (2015) Antiangiogenic effects of cucurbitacin-I. Archives of Pharmacal Research, 38, 290–298.
29.
JinK.H., ParkJ.H.Y., Jin-KyungK. (2014) Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer. Chemico-Biological Interactions, 219, 1–8.
30.
EyolE., BoleijA., TaylorR.R., LewisA.L., BergerM.R. (2008) Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clinical & Experimental Metastasis, 25, 273–282.
31.
KaleağasioğluF., BergerM.R. (2014) Differential effects of erufosine on proliferation, wound healing and apoptosis in colorectal cancer cell lines. Oncology Reports, 31, 1407–1416.
32.
TekedereliI., AlpayS.N., AkarU., YucaE., Ayugo-RodriguezC., HanH.D., SoodA.K., Lopez-BeresteinG., OzpolatB. (2013) Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Molecular Therapy-Nucleic Acids, 2, e121.
